SCP-111 Autoinjector achieved primary pharmacokinetic and secondary pharmacodynamic endpoints The autoinjector is being developed to deliver a subcutaneous injection of furosemide as an alternative option to the FDA approved FUROSCIX on-body infusor presentation Company targeting Supplemental New Drug Application (sNDA) submission to the FDA by year-end 2024 BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the "Company"), a pharmaceutical company focused on develop ...